Ranbaxy Of India Awaits U.S. Court Ruling On Fate Of Lipitor Generic
This article was originally published in PharmAsia News
Executive SummaryIndia's Ranbaxy Laboratories expects to learn this week whether it can launch a generic on the U.S. market of local drug-maker Pfizer's Lipitor (atorvastatin) the world's best-selling drug
You may also be interested in...
Pfizer has announced that it does not plan to market its Amsparity adalimumab biosimilar in Europe despite it having been endorsed by the EMA in December and being in line for an imminent approval from the European Commission.
Developers of arthroscopy tubing should take additional steps to reduce the risk of patient cross-contamination, the US FDA recommends in a new draft guidance document.
A revised procedure is in place to temporarily list unlicensed products for use in public health emergencies.